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Abstract
Cohort studies of large series of patients with sarcoidosis over a long period of time are scarce. The aim of this study is to report a 40-
year clinical experience of a large series of patients at Bellvitge University Hospital, a tertiary university hospital in Barcelona, Spain.
Diagnosis of sarcoidosis required histological confirmation except in certain specific situations. All patients underwent a prospective
study protocol. Clinical assessment and follow-up of patients were performed by a multidisciplinary team.
From 1976 to 2015, 640 patients were diagnosed with sarcoidosis, 438 of them (68.4%) were female (sex ratio F/M 2:1). Themean
age at diagnosis was 43.3±13.8 years (range, 14–86 years), and 613 patients (95.8%) were Caucasian. At diagnosis, 584 patients
(91.2%) showed intrathoracic involvement at chest radiograph, and most of the patients had normal pulmonary function. Erythema
nodosum (39.8%) and specific cutaneous lesions (20.8%) were the most frequent extrapulmonary manifestations, but there was a
wide range of organ involvement. A total of 492 patients (76.8%) had positive histology. Follow-up was carried out in 587 patients
(91.7%), over a mean of 112.4±98.3 months (range, 6.4–475 months). Corticosteroid treatment was administered in 255 patients
(43.4%), and steroid-sparing agents in 49 patients (7.7%). Outcomeswere as follows: 111 patients (18.9%) showed active disease at
the time of closing this study, 250 (42.6%) presented spontaneous remission, 61 (10.4%) had remission under treatment, and 165
(28.1%) evolved to chronic sarcoidosis; among them, 115 (19.6%) with mild disease and 50 (8.5%) with moderate to severe organ
damage. A multivariate analysis showed that at diagnosis, age more than 40 years, the presence of pulmonary involvement on chest
radiograph, splenic involvement, and the need of treatment, was associated with chronic sarcoidosis, whereas Löfgren syndrome
and mediastinal lymphadenopathy on chest radiograph were indicators of good outcome.
Sarcoidosis is a multisystem disease with protean clinical-radiographic manifestations. Although almost half of patients follow a
spontaneous resolution or under treatment, a significant number of them may have several degrees of organ damage. This study
emphasizes the value of a multidisciplinary approach and long-term follow-up by specialized teams in sarcoidosis.
Abbreviations: BHL = bilateral hilar lymphadenopathy, CNS = central nervous system, CT = computer tomography, DLco =
diffusing capacity for carbon monoxide, EBUS-TBNA = endobronchial ultrasound-guided transbronchial needle aspiration, FDG
PET/CT = Fluorodeoxyglucose F 18 combined positron emission tomography and computer tomography, FEV1 = forced expiratory
volume in 1st second, FVC = forced vital capacity, PFT = pulmonary function tests, PPD = tuberculin purified protein derivate skin
test, SACE = serum angiotensin converting enzyme, SURT = sarcoidosis of the upper respiratory tract.
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Sarcoidosis is a multisystem disease of unknown etiology,
characterized by the presence of non-caseating granulomatous
inflammation in 1 or more organs.[1] Although the diagnosis
warrants a tissue biopsy, in special situations a presumptive
diagnosis may be made based on clinical-radiographic findings
alone. The exclusion of other granulomatous diseases is equally
essential.[2] From the first descriptions of the disease in the 19th
century, knowledge has expanded across multiple fields such as
epidemiology, etiology, genetics, pathogenesis, and also with
regard to clinical aspects, including treatment, evolution, and
prognosis.[2–4] The clinical expression of sarcoidosis and the
long-term natural history of the disease may vary according to
different ethnicities and countries.[5–7] During the second half of
the last century, a number of reports, including several historical
series of patients describing the general clinical characteristics
and prognosis of the disease, contributed to the clinical
knowledge of sarcoidosis.[8–26] However, observational studies
of large series of patients over a long period of time are scarce.
One of the most outstanding studies was the revision by Johns
and Michele[27] at the Johns Hopkins University School of
Medicine in Baltimore, MD in which the authors reported a 50-
year experience at the institution, mainly focusing on clinical
presentation, case series, issues in clinical management and
extrathoracic manifestations of sarcoidosis. However, the data
relating to the series of patients was reported in a fractioned way,
and an overall view of the series as a whole was not provided.[31]
In our institution, the Bellvitge University Hospital in
Barcelona, Spain, the care of patients with sarcoidosis started
during the mid-1970s in a special unit devoted to this disease.
Since then, the everyday care of these patients has been carried
out in close collaboration with a multidisciplinary team
comprising different specialists. The senior author of this paper
has become involved in the clinical assessment and management
of patients with sarcoidosis from the beginning of the unit, and
since 1992, he has been the director of the group. The aim of this
study is to present an observational and prognostic investigation
of a large cohort of patients with sarcoidosis, studied
prospectively and followed up at our institution over the last 4
decades.2. Methods
2.1. Diagnosis of sarcoidosis
During the period 1976 to 2015, 640 patients were diagnosed
with sarcoidosis at the Bellvitge University Hospital, an 800-bed
tertiary university hospital in Barcelona, Spain. The criteria for
acceptance of a diagnosis of sarcoidosis were: a compatible
clinical and radiological picture; histological demonstration of
non-caseating granulomas in 1 or more tissues with negative
stains and cultures for mycobacteria and fungus, or, a positive
Kveim–Siltzbach skin test; and exclusion of other granulomatous
diseases. One positive biopsy was considered enough if the
thoracic radiology was consistent with sarcoidosis, while 2 or
more were required, if available, when the radiology was normal
or not typical for sarcoidosis. The diagnosis of sarcoidosis was
accepted without histological confirmation in the following
circumstances: patients with Löfgren syndrome; asymptomatic
finding of typical bilateral hilar lymphadenopathy (BHL), both in
a chest radiograph with a lambda pattern in 67-gallium scan and
increased serum angiotensin converting enzyme (SACE) level, or
in a thoracic computed tomography (CT); a CT pulmonary2
pattern typical for sarcoidosis with or without a bronchoalveolar
lavage with a lymphocytic alveolitis and a CD4/CD8 >3.5.
During the period 1977 to 1981, the Kveim–Siltzbach suspen-
sions were provided by the Royal Brompton Hospital, London,
UK, and from 1996 to 2000 by the Mount Sinai Medical Center,
New York, NY.2.2. Definitions and classifications
The chest radiograph stages were classified according to the
Scadding criteria.[15] Doubtful or atypical hilar lymph node
enlargement and/or pulmonary involvement on chest radiograph
were confirmed by 67-gallium scan and/or thoracic CT. Löfgren
syndrome was defined as the association of erythema nodosum
and/or periarticular ankle inflammation with BHL with or
without pulmonary involvement. Extrapulmonary organ in-
volvement was defined according to previous reported crite-
ria.[28,29] Since 2011, Fluorodeoxyglucose F 18 combined
positron emission tomography and computer tomography
(FDG PET/CT) substituted the practice of 67-gallium scan.
FDG PET/CT was performed only in selected cases according to
the indications, such as initial assessment of difficult cases,
looking for hidden activity sites on which to perform a biopsy,
and assessment of activity in patients with chronic fibrotic
pulmonary sarcoidosis for assessing treatment.[30]2.3. Study protocol
Since 1976, the patients diagnosed with sarcoidosis were
submitted to a prospective study protocol at diagnosis. During
2015, the protocols were transferred to a recently created ACCES
(Microsoft Office Access Database 2003) database. The study
protocol included a clinical history and physical examination
(including ocular examination), chest radiograph, general
hematologic, and biochemical exams, including (SACE) level,
tuberculin purified protein derivate skin test (PPD), and
pulmonary function tests (PFT), including spirometry, pulmo-
nary volumes, and diffusing capacity for carbon monoxide.
Other ancillary tests to assess both intrathoracic and extrap-
ulmonary sarcoidosis and the types of biopsies were performed
according to clinical indications and involved organs. In order to
assess changes in clinical aspects of sarcoidosis over time, and
investigate whether the advent of more advanced imaging
techniques had some impact in the detection of organ involve-
ment, a comparison was made between the first 2 and last 2
decades of the study. Data regarding treatment and outcomewere
collected from patients who were followed up. No specific
therapeutic schedule was followed, and corticosteroids and other
immunosuppressive agents were administered according to
indications recommended in medical literature.[31] Patients were
followed up every 3 to 6months until the disease became inactive,
and thereafter, once a year.
The prospective study protocol, diagnosis of sarcoidosis,
adjudication of outcomes, and treatment decisions, were always
made ultimately by the leading physician of the group, F. Badrinas
(see acknowledgements) from 1976 to 1992 and J. Mañá from
1992 to 2015. They personally evaluated all the patients so the
criteria were completely homogeneous. Any patient with a
suspicion of sarcoidosis initially seen by other specialists was
referred to the outpatient sarcoidosis clinic. According to the type
of organ involvement and treatment requirements, the patients
were periodically discussed in clinical sessions with the participa-
tion of the members of the multidisciplinary team constituted by
Table 1
Mode of onset of sarcoidosis in 640 patients.
Patients n (%)
Löfgren syndrome 263 (41.1%)
Mañá et al. Medicine (2017) 96:29 www.md-journal.comspecialists in Internal Medicine, Pulmonary, Dermatology,
Ophthalmology, Pathology, Neurology, Radiology, Nuclear
Medicine, and others. The present study was approved by the
Ethics Committee at Bellvitge University Hospital.Erythema nodosum 225 (35.2%)
Periarticular ankle inflammation without erythema nodosum 38 (5.9%)
Respiratory symptoms (cough, dyspnea) 101 (15.8%)
Specific (granulomatous) cutaneous lesions 60 (9.4%)
Asymptomatic finding on chest radiograph or thoracic CT 54 (8.4%)
Articular involvement other than periarticular ankle inflammation 36 (5.6%)
Fever 26 (4.1%)
Neurological symptoms 23 (3.6%)
Ocular 22 (3.4%)
Peripheral lymph nodes 19 (3%)
Parotid enlargement 5 (0.8%)
Hypercalcemia 3 (0.5%)









CT= computed tomography; SURT= sarcoidosis of upper respiratory tract.
Table 2
Radiological stages at diagnosis in 640 patients.
Chest radiograph stage Patients n (%)
Stage 0 56 (8.8%)
Stage I 387 (60.5%)
Stage II 143 (22.3%)
Stage III 42 (6.5%)
Stage IV 12 (1.9%)2.4. Outcomes assessment
The outcomes of sarcoidosis were classified according to the
presence or absence of ongoingdisease after 2 years, between2 and
5 years, and more than 5 years (chronic disease) from diagnosis.
Chronic sarcoidosis was classified as having mild or moderate to
severe organ damage.Organ damagewas defined as disease sequel
of sarcoidosis that is not reversible, and therefore unlikely to
respond to immunosuppressant agents or resolve on its own. In the
absenceof validated criteria,moderate to severeorgandamagewas
defined as the presence of 1 of the following: radiological signs of
pulmonary fibrosis and forced vital capacity (FVC) <60% of
predicted and/or diffusing capacity for carbon monoxide (DLco)
<50% of predicted, presence of moderate to severe pulmonary
hypertension suggested by echocardiogram (systolic pulmonary
arterial pressure>40mmHg), neurosarcoidosiswith sequel (other
than facial nerve palsy), cardiac sarcoidosis, chronic cutaneous
involvement (plaques and lupus pernio), chronic uveitis, chronic
renal failure, portal hypertension, or chronic symptomatic bone
involvement. Relapse was defined as the reappearance of the
disease during the decreasing phase or until 2 years after the
suppression of treatment. Recurrence was defined as the
reappearance of the disease after at least 1 year of spontaneous
remission.[32] To examine factors predicting chronic sarcoidosis, a
series of variables at diagnosis including age, sex, organ
involvement, PFT, SACE, and need of treatment were analyzed.
2.5. Statistical analysis
A descriptive analysis was performed, by expressing the results as
means and standard deviations for continuous variables, and
absolute values and percentages for categorical variables. A t test
(and Mann–Whitney U test in the absence of parametric
distribution) was performed for the comparison between continu-
ous variables, and the chi-square test or Fisher exact test, when
appropriate, for the comparison of categorical variables. A
univariate and multivariate analyses by means of binary logistic
regressionwere performed in order to assess the prognostic factors
at diagnosis related to chronic sarcoidosis. Those variables that
reached statistical significance in the univariate analysis were
introduced in the multivariate analysis. SPSS (SPSS 15.0. 2009,
Chicago, IL) was used for statistical analyses (P< .05).
3. Results
3.1. Demographic data and clinical presentation
Six hundred and forty patients were diagnosed with sarcoidosis
over 40 years at Bellvitge University Hospital in Barcelona, Spain.
Four hundred and thirty-eight patients (68.4%) were women and
202 (31.6%) were men (sex ratio F/M 2:1). The mean age at
diagnosis was 43.3±13.8 years (age range, 14–86). Six hundred
and thirteen patients (95.8%) were Caucasian, 14 (2.2%) North
African, 5 (0.8%) Hispanic, 5 (0.8%) Black, and 3 (0.4%) Asian.
At diagnosis, 498 patients (79.4%) were non-smokers, 67
(10.7%) smokers, 62 (9.9%) former smokers, and 13 had no data
regarding smoking behavior. Fifteen patients (2.3%) in 9 families
had familial sarcoidosis. The time between the onset of symptoms
and diagnosis was less than 6 months in 418 patients (71.3%),3
and more than 6 months in 168 (28.7%). Table 1 shows the
clinical presentation of sarcoidosis.3.2. Pulmonary and extrapulmonary manifestations
Two hundred patients (31.3%) complained of respiratory
symptoms (dyspnea and/or cough). Table 2 shows the chest
radiograph stages and Table 3 the relationship with thoracic CT,
both at diagnosis. In most patients, PFT were within the normal
range at diagnosis (Table 4). Table 5 shows the relationship
between functional respiratory patterns and the chest radiograph
stages at diagnosis. The presence of pulmonary involvement
correlated with decline in pulmonary function. Pulmonary
hypertension was detected at some stage of the follow-up in 8
patients (1.3%).
Table 6 illustrates the findings of extrapulmonary manifes-
tations, by organ involvement occurring during the first 6 months
after diagnosis (first column), and in a detailed clinical expression
at some time during the follow-up (second column). The skin was
the second organ involved after the lung either as erythema
nodosum or as specific (granulomatous) cutaneous lesions. It was
not infrequent to findmore than 1 type of skin lesion coexisting in
the same patient. Table 7 shows a comparison of specific organ
involvement in the present study and 2 other historical large series
of sarcoidosis.[6,33]
Table 3












Stage 0 15 (42.9%) 12 (34.3%) 5 (14.3%) 3 (8.6%) 35 (11.2%)
Stage I 0 115 (70.1%) 49 (29.9%) 0 164 (52.4%)
Stage II 0 10 (12.7%) 67 (84.8%) 2 (2.5%) 79 (25.2%)
Stage III 0 2 (7.7%) 12 (46.2%) 12 (46.2%) 26 (8.3%)
Stage IV 0 0 6 (66.7%) 3 (33.3%) 9 (2.9%)
Total patients 15 (4.8%) 139 (44.4%) 139 (44.4%) 20 (6.4%) 313
CT= computed tomography.
Table 4
Pulmonary function tests at diagnosis.
















DLco=diffusing capacity of carbon monoxide, FEV1= forced expiratory volume in 1st second, FVC=
forced vital capacity, PFT=pulmonary function tests.
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PPD was negative in 447 out of 513 patients (87.1%). One
hundred and sixty-five of 436 patients (37.8%) showed hyper-
gammaglobulinemia at diagnosis. SACE levels at diagnosis were
increased in 278 out of 543 patients (51.2%) in whom SACE had
been performed. 67-gallium scan was performed in 406 patients
at diagnosis. Increased uptake was present in mediastinal lymph
nodes in 339 patients (83.5%), in pulmonary parenchyma in 96
(23.5%), and in parotid and salivary glands in 74 (18.1%).
Twenty-nine patients (7.1%) did not show increased 67-gallium
uptake. FDG PET-CT was performed in 85 patients either at
diagnosis or at any time during the follow-up. Mediastinal
involvement was present in 62 patients (42.5%), pulmonaryTable 5
Relationship among pulmonary function test patterns and chest radio
patients underwent complete functional tests. Chi-square test.
PFT pattern at diagnosis Stage 0 Sta
Normal (FVC ≥80%, FEV1 ≥80%, and DLco ≥80%) 25 (69.4%) 175 (6
Restrictive (FVC <80%) 6 (16.7%) 25 (8
Obstructive (FEV1 <80%) 5 (13.9%) 35 (1
DLco <80% 7 (20.6%) 62 (2
DLco=diffusing capacity of carbon monoxide, FEV1= forced expiratory volume in 1 second, FVC= forc
4
parenchyma in 36 (24.7%), and extrapulmonary sites in 34
(23.3%). Table 8 displays the different types of positive biopsy
procedures.3.4. Treatment, follow-up, and outcome
A total of 587 patients (91.7%) were followed-up and 53 (8.3%)
were not, since they had been referred to our sarcoidosis unit
from other hospitals only for diagnosis assessment. The mean
follow-up was 112.4±98.3 months (range, 6.4–475 months). Of
this group, 266 (45.3%) received treatment for at least 3 months
at some time during the follow-up. Corticosteroid treatment was
administered in 255 patients (43.4%). Steroid-sparing agents,
usually with a low-dose of corticosteroids, or a combination of
them, were administered as follows: methotrexate in 25 patients
(4.3%), antimalarials in 23 (4%), and azathioprine in 22 (3.7%).
Other agents were used in a few cases: mycophenolate mofetil in 8
patients, cyclosporine in 3, infliximab in 3, minocycline in 2,
cyclophosphamide in 2, rituximab in 2, and pentoxifylline in 1.
Table 9 summarizes the overall outcome of the 587 patients
that were followed-up. One hundred and eleven patients (18.9%)
showed active disease at the time of closing the present study.
Two hundred and fifty patients (42.6%) showed spontaneous
remission without treatment. Sixty-one patients (10.4%) had
remission under treatment. One hundred and sixty-five patients
(28.1%) showed active disease more than 5 years after diagnosis
and were classified as chronic sarcoidosis. Among these, 115
patients (19.6%) showed mild activity and 50 patients (8.5%)
were classified as having moderate to severe organ damage. The
most frequently damaged organ was the lung (particularly
pulmonary fibrosis), the nervous system, and the skin. Four
patients are currently under assessment for pulmonary trans-
plantation, and 1 is under hemodialysis and being assessed for a
kidney transplant. One patient had a complication of mycetoma.
Thirty out of 266 treated patients (11.3%) presented relapse after
decreasing the dose of corticosteroids or the suppression ofgraph stage at diagnosis. Percentages do not add up since not all
Chest radiograph at diagnosis
ge I Stage II Stage III Stage IV P
5.8%) 43 (36.8%) 10 (29.4%) 0 <.001
.5%) 32 (25.8%) 13 (37.1%) 4 (66.7%) <.001
1.9%) 43 (34.7%) 19 (54.3%) 5 (83.3%) <.001
3.7%) 45 (42.5%) 15 (45.5%) 4 (100%) <.001
ed vital capacity, PFT=pulmonary function tests.
Table 6
Extrapulmonary sarcoidosis at diagnosis or at any time during the follow-up in 640 patients.




Extrapulmonary manifestations Patients n (%) Patients n (%)
Löfgren syndrome 296 (100) 296 (46.2)
Erythema nodosum 255 (39.8)
Periarticular ankle inflammation without erythema nodosum 41 (6.4)
Arthralgia/itis other than periarticular ankle inflammation 220 (92.1) 239 (37.3)
Fever 147 (97.4) 151 (23.6)
Fever with Löfgren syndrome 103 (16.1)
Fever without Löfgren syndrome 48 (7.5)
Specific granulomatous skin lesions 108 (81.2) 133 (20.8)
Maculopapules 74 (11.6)
Plaques 93 (81.6) 42 (6.6)
Subcutaneous nodules 92 (81.4) 28 (4.4)
Scar sarcoidosis 18 (2.8)
Lupus pernio 8 (1.3)
Peripheral lymph nodes 114 (17.8)
Liver involvement 113 (17.7)
Cholestasis 83 (13)
Hepatomegaly 50 (7.8)
Liver nodules on CT 6 (0.9)
Portal hypertension 4 (0.6)
Disabling asthenia 48 (77.4) 62 (9.7)
Neurological involvement 39 (76.5) 51 (8)
Cranial nerves 28 (4.4)
VII cranial nerve/bilateral VII cranial nerve 20 (3.1)/8 (1.3)
X cranial nerve 4 (0.6)
VIII cranial nerve 3 (0.5)
V cranial nerve 3 (0.5)
III cranial nerve 2 (0.3)
II cranial nerve 1 (0.2)
VI cranial nerve 1 (0.2)
IX cranial nerve 1 (0.2)
XII cranial nerve 1 (0.2)
Seizures 7 (1.1)
Peripheral neuropathy 6 (0.9)
Hypothalamic and pituitary gland involvement 5 (0.8)
Periventricular white matter lesions 5 (0.8)
Meningitis 4 (0.6)
Parenchymal brain lesion 4 (0.6)
Spine cord involvement 3 (0.5)
Small fiber neuropathy 3 (0.5)
Hydrocephalus 2 (0.3)
Encephalopathy 2 (0.3)
Cerebral vascular involvement 2 (0.3)
Psychiatric symptoms 1 (0.2)
Pyramidal/sensitive syndrome 1 (0.2)
Cerebellum 1 (0.2)
Ocular involvement 43 (87.8) 49 (7.7)
Anterior uveitis 43 (6.7)
Intermediate/posterior uveitis 17 (2.7)
Splenic involvement 40 (83.3) 48 (7.5)
Splenomegaly 34 (5.3)
Splenic nodules on CT 17 (2.7)
Pancytopenia 6 (0.9)
Hypercalcemia 23 (69.7) 33 (5.2)
Parotid/salivary glands/lacrimal 18 (75) 24 (3.8)
SURT 10 (45.5) 22 (3.4)
Bone involvement 10 (47.6) 21 (3.3)
Renal involvement (chronic renal failure, nephritis, or proteinuria) 10 (76.9) 13 (2)
Muscular involvement 6 (100) 6 (0.9)
Cardiac involvement 3 (60) 5 (0.8)
Breast 2 (66.7) 3 (0.5)
Vulva 1 (50) 2 (0.3)
Bone marrow 0 2 (0.3)
CT= computed tomography, SURT=Sarcoidosis of upper respiratory tract.
∗
The percentage of those manifestations in the first 6 months after diagnosis is related to the involvement of that particular organ.
∗∗
Some patients presented diverse manifestations affecting the same organ, so the total count on each organ involvement does not add up to 100%.
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Table 7








Number of patients 3676 736 640
Lung
Stage 0 8% 8.3% 8.8%
Stage 1 51% 39.7% 60.5%
Stage 2 29% 36.7% 22.3%
Stage 3 12% 9.8% 6.5%
Stage 4  5.4% 1.9%
Skin 9% 15.9% 20.8%
Lymph node 22% 15.2% 17.8%
Eye 15% 11.8% 7.7%
Liver  11.5% 17.7%
Erythema nodosum 17% 8.3% 39.8%
Spleen 6% 6.7% 7.5%
Neurologic 4% 4.6% 8.8%
Parotid/salivary 4% 3.9% 1.9%
Bone marrow  3.9% 0.3%
Calcium 11% 3.7% 5.2%
SURT  3% 3.4%
Cardiac  2.3% 0.8%
Renal  0.7% 2.7%
Bone 3% 0.5% 3.3%
Muscle  0.4% 0.9%
SURT= sarcoidosis of upper respiratory tract.
Table 8
Histological diagnosis of sarcoidosis. Percentage was calculated
in basis of the total of the series, including patients without
histological confirmation.
Biopsies Patients n (%)
Diagnosis without biopsy 148 (23.2%)
Löfgren syndrome 129 (20.2%)
Non-Löfgren syndrome 19 (3%)
Diagnosis with biopsy 492 (76.8%)
Skin 149 (23.3%)
Kveim–Siltzbach skin test 91 (14.2%)
Muscle 77 (12%)
Peripheral node 68 (10.6%)
Transbronchial 64 (10%)
Liver 50 (7.8%)
Mediastinal node (mediastinoscopy) 36 (5.6%)





Parotid/salivary/lacrimal gland 13 (2%)
SURT 12 (1.9%)













CNS= central nervous system, EBUS= endobronchial ultrasound, SURT= sarcoidosis of upper
respiratory tract.
Table 9
Patients’ classification throughout a 40-year follow-up. Part of the
cohort cannot be classified since they are patients yet on activity
and others due to lack of follow-up, so that numbers do not add up.
Different severe organ damage can be present in the same patient,
so numbers do not add up as well.
Outcome Patients n (%)
Patients diagnosed and without follow-up 53/640 (8.3%)
Classifiable patients 587/640 (91.7%)
Classifiable patients in <2 years from diagnosis 321/587 (54.7%)
Spontaneous remission 209/587 (35.6%)
Remission under treatment 34/587 (5.8%)
Patients with follow-up <2 years and still active 78/587 (13.3%)
Classifiable patients 2–5 years from diagnosis 101/587 (17.2%)
Spontaneous remission 41/587 (7%)
Remission under treatment 27/587 (4.6%)
Patients still active 2–5 years from diagnosis 33/587 (5.6%)
Chronic sarcoidosis (activity >5 y) 165/587 (28.1%)
Mild activity 115/587 (19.6%)
Moderate to severe organ damage 50/587 (8.5%)
Pulmonary damage




Chronic posterior uveitis 3/50
Liver cirrhosis/portal hypertension 3/50
Bone involvement 2/50
Cardiac involvement 2/50
Chronic renal failure 2/50
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therapy. Twenty-two out of 587 patients (3.7%), 21 Löfgren, and
1 non-Löfgren, had recurrence of the disease years after
spontaneous remission without treatment. Nine out of 587
patients (1.5%) died due to causes related to sarcoidosis (6
pulmonary fibrosis, 2 pulmonary hypertension, and 1 portal
hypertension).3.5. Predictor factors at diagnosis of chronic sarcoidosis
Table 10 shows the results of univariate and multivariate analysis
of factors at diagnosis predicting active disease at 5 years (chronic
sarcoidosis, including both mild and moderate to severe organ
damage). Age more than 40 years, the presence of pulmonary
involvement on chest radiograph, splenic involvement, and the
need of treatment (both corticosteroids and steroid-sparing
agents) were associated with a poor prognosis. Löfgren syndrome
and the presence of mediastinal lymphadenopathy on chest
radiograph were associated with a good outcome.
Table 11 shows the comparison between the first 2 and last 2
decades of the study as regards age of diagnosis, extrapulmonary
organ involvement, treatment with steroid-sparing agents, and
mortality.4. Discussion
The present study describes our 40-year clinical experience of a
large cohort of 640 consecutive patients with sarcoidosis at
Bellvitge University Hospital, Barcelona, Spain. Most of our
patients were Caucasians, because immigration in Spain has been
minimal until recently. Since there is no reliable official
epidemiological data on sarcoidosis in our country, this large
series of patients and its prolonged period of follow-up provide a
representation of the situation of sarcoidosis in Spain.
Table 10
Predictor factors at diagnosis of chronic sarcoidosis in 165 patients.
Univariate analysis OR P Multivariate analysis OR P
Age >40 1.80 .001 1.93 .038
Gender (male) 1.47 .040  
Mediastinal lymph nodes on chest radiograph (I, II) 0.32 <.001 0.49 .062
Pulmonary involvement on chest radiograph (II, III, IV) 4.09 <.001 3.30 <.001
FVC <70% 2.95 .003  
FEV1 <70% 3.08 <.001  
DLco <70% 2.00 .002  
Hypergammaglobulinemia 1.52 .054  
Increased SACE 1.47 .031  
Hypercalcemia 1.18 .722
Löfgren syndrome 0.14 <.001 0.43 .020
Peripheral lymph nodes 1.68 .029  
Maculopapules/sc nodules/scar 0.99 .960
Plaques/lupus pernio 2.47 .006  
Liver involvement 2.06 .002  
Splenic involvement 3.23 <.001 5.31 .004
Facial nerve palsy (without other neurological involvement) 2.75 .062
Neurological involvement (other than facial nerve palsy) 3.08 .012  
Anterior uveitis 1.42 .318
Intermediate/posterior uveitis 0.59 .503
Parotid/salivary glands/lacrimal involvement 3.43 .007  
SURT 2.73 .116
Bone involvement 1.94 .263
Renal involvement 1.35 .630
Muscular involvement 0.53 .567
Cardiac involvement 5.41 .169
Use of steroids 9.65 <.001 3.78 <.001
Use of steroids-sparing agents 13.17 <.001 3.45 .022
DLco=diffusing capacity of carbon monoxide, FEV1= forced expiratory volume in 1st second, FVC= forced vital capacity, OR=odds ratio, SACE= serum angiotensin-converting enzyme, SURT= sarcoidosis of
the upper respiratory tract.
Mañá et al. Medicine (2017) 96:29 www.md-journal.com4.1. Mode of presentation of sarcoidosis
Knowledge of the wide variety of presentations of sarcoidosis is
crucial in initial diagnostic suspicion.[34] The most outstanding
feature of this series was the high frequency of erythema nodosum
as a way of onset of the disease. The high frequency of LöfgrenTable 11
Mean age, extrapulmonary sarcoidosis, use of steroid-sparing age
categorical variables and t test for quantitative variables.
Patients n (%
Age at diagnosis (y) mean (SD) 4
Extrapulmonary manifestations
Löfgren syndrome










Renal involvement (chronic renal failure, nephritis, or proteinuria)
Muscular involvement
Cardiac involvement
Use of steroid-sparing agents
Mortality due to sarcoidosis
SD= standard deviation, SURT= sarcoidosis of upper respiratory tract.
7
syndrome in Spain had been already reported in a cooperative
study among 3 hospitals in Barcelona, performed more than 20
years ago.[24] Several studies have also described a high
prevalence of Löfgren syndrome in northern European coun-
tries.[35,36] It has been hypothesized that Löfgren syndrome is a
consequence of a combination of environmental factors, with ants and mortality over time. Chi-square or Fisher exact test for
) 1976–1995 N=353 Patients n (%) 1996–2015 N=287 P
0.6 (13) 46.6 (14.1) <.001
199 (56.8) 97 (34.4) <.001
48 (13.6) 85 (29.6) <.001
63 (17.8) 51 (17.8) .932
64 (18.1) 49 (17.1) .657
23 (6.5) 28 (9.7) .133
23 (6.5) 26 (9) .230
26 (7.4) 22 (7.6) .996
13 (3.7) 20 (6.9) .062
8 (2.3) 16 (5.6) .018
2 (0.6) 20 (6.9) <.001
8 (2.3) 13 (4.5) .110
4 (1.1) 9 (3.1) .093
0 6 (2.1) .008
3 (0.8) 2 (0.7) .915
16 (4.5) 48 (16.7) <.001
7 (2) 2 (0.7) .197
[37]
Mañá et al. Medicine (2017) 96:29 Medicinegenetic predisposition. Earlier studies showed that symptoms
of erythema nodosum were, significantly, first noticed during
springtime.[36,38,39] In addition, a genetic study involving
Swedish and Spanish patients confirmed previous reports that
the CCR2 haplotype 2 andHLA-DRB1∗0301 were independent
risk factors predisposing to Löfgren syndrome.[36,37,40] A small
but significant number of patients (6.4%) presented only with
ankle swelling without erythema nodosum, which is considered a
variant of Löfgren syndrome.[35,39,41]
Three other forms of presentations in our series deserve some
comments. In spite of 91% of our patients having intrathoracic
radiographic involvement, respiratory symptoms were the way of
presentation in only 16% of cases, which corroborates the
frequent clinical-radiographic dissociation seen in sarcoidosis. A
systemic work-up for sarcoidosis is indicated in any patient
presenting with granulomatous cutaneous lesions (9.4% in our
series).[42] In previous reports we have stressed the presence of
papules in the knees as a frequent form of onset of systemic
sarcoidosis.[43,44] Not infrequently, sarcoidosis is discovered by
chance in a chest radiograph or a thoracic CT performed for
other reasons (8.4% in our series).[45] Currently, the detection of
sarcoidosis as an asymptomatic finding has increased with the use
of FDG PET/CT scan performed during the follow-up of patients
with cancer.[46] The wide clinical variety of the other forms of
presentations shown in Table 1 highlights the multisystem nature
of sarcoidosis.4.2. Pulmonary sarcoidosis
The chest radiograph stages distribution based on Scadding
classification in our series is in concordance with most series of
sarcoidosis.[2] Thoracic CT was performed in 49% of our
patients. Significantly, it demonstrated the presence of pulmonary
involvement in 23% of patients with stage 0, and in 30% of those
with stage I on chest radiograph. However, this finding by itself is
not an indication for treatment, unless there is the concomitant
presence of respiratory symptoms and/or decline in respiratory
function.[47] In sarcoidosis, thoracic CT is considered more
important as a diagnostic modality than for treatment indica-
tions.[4] However, it should not be performed systematically in
patients with a typical chest radiograph.[48] Most of our patients
showed normal PFT at diagnosis. This finding reaffirms that
clinical-radiographic dissociation is also extensive to pulmonary
function in sarcoidosis. In our series the most frequent impair-
ments were restrictive and/or obstructive patterns and/or
decrease in DLco. Concomitant irreversible airflow obstruction
is frequently present in stage IV. Although there is a significant
overlap between radiological stages and impairment of PFT (as
shown in Table 5), in general, the more advanced the radiological
stage, the greater the decline in functional status. FVC is
considered the simplest andmost accurate parameter to reflect the
impact of pulmonary involvement.[49,50]4.3. Extrapulmonary sarcoidosis
The frequency of extrapulmonary manifestations in our cohort of
patients agrees with other large international series.[6,7,33] The
skin, specific (granulomatous) cutaneous lesions, was the second
organ involved after the lung. The more frequent granulomatous
cutaneous lesions were maculopapules and plaques. Lupus
pernio, that has been reported to be frequent in African American
and West Indian patients, with a woman predominance, and a
hallmark of chronicity,[51–53] is not frequent in Spain. Mild8
cholestasis caused by granulomatous hepatitis is common, while
severe cholestasis and portal hypertension are rare. It is important
to recognize the presence of low-attenuation nodules on CT on
the liver and spleen as a not infrequent finding of sarcoidosis.[3]
Eye involvement was not frequent in our series, in spite of
systematically performing an ophthalmologic examination in the
initial assessment.
Neurosarcoidosis was present in 8% of patients in our series.
The most frequent manifestation was cranial neuropathy,
particular facial palsy, sometimes bilateral. Leptomeningeal
involvement, either as aseptic meningitis or as focal or diffuse
gadolinium meningeal enhancement on MRI, on isolation or
associated with cranial neuropathies, is a common abnormality
in neurosarcoidosis and occasionally may result in hydrocepha-
lus. The hypothalamus and the pituitary gland are the most
frequent parenchymal brain involvement and may result in
endocrinopathies. However, as shown in Table 6, any region of
the brain and spinal cord can be involved, resulting in a variety of
neurological symptomatology. Periventricular white matter
lesions onMRI are not infrequently seen, but they are considered
non-specific. Peripheral neuropathy is uncommon and small fiber
neuropathy causing disabling pain is being increasingly recog-
nized.[54]
Table 6 also shows that other forms of extrapulmonary
involvement, such as hypercalcemia and salivary and lacrimal
glands, were less frequent. Recognition of sarcoidosis of the
upper respiratory tract (SURT) is important since subtle
symptoms of nasal obstruction may be overlooked by physi-
cians.[55] Bone sarcoidosis is being detected with increasing
frequency in asymptomatic patients following the introduction of
FDG PET/CT. Renal involvement is usually a consequence of
granulomatous or lymphocytic interstitial nephritis.[56] Symp-
tomatic muscle involvement is rare. Cardiac sarcoidosis is very
uncommon and difficult to recognize, although is frequent in
Japan.[57] Apart from the different organs involved, a consider-
able burden of disease may be caused by nonspecific but
troublesome symptoms, termed by Lazar and Culver as
“sarcoidosis penumbra.” [31] The most significant is fatigue,
which accounted for almost 10% of patients in our series. Fatigue
may be present even when the disease is already in remission, and
may frequently be accompanied by depression and impair quality
of life.[58,59]
Interestingly, although most extrapulmonary organ involve-
ment took place in the first 6 months after diagnosis, some organs
were affected during follow-up. Therefore, longitudinal screening
should be maintained over time.[60] Only symptoms related to
Löfgren syndrome always occurred at onset.4.4. Histological diagnosis
One positive biopsy may be sufficient when clinical-radiographic
findings are typical; otherwise, 2 or more may be necessary.
However, in some classic presentations, such as Löfgren
syndrome, asymptomatic BHL, and Heerfordt syndrome, the
diagnosis can be accepted without histological support.[4] Given
the multisystem nature of the disease, a wide variety of biopsies
have been used in sarcoidosis. Currently, endobronchial
ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) is becoming the diagnostic procedure of choice in many
centers because of high sensitivity and low complications rate,
and it is replacing the practice of mediastinoscopy and trans-
bronchial lung biopsy.[61,62] Conjunctival and nasal mucosa
biopsies also have a high yield, and their practice has been
Mañá et al. Medicine (2017) 96:29 www.md-journal.comrecommended as silent sites of granulomatous inflammation in
patients with diagnostic difficulties, for instance, in isolated
neurosarcoidosis. However, the demonstration of granuloma-
tous inflammation by itself is not specific to sarcoidosis, and a
differential diagnosis with other granulomatous diseases,
according to the involved organ, is mandatory.[2]4.5. Treatment, follow-up and outcome
In sarcoidosis there is often a struggle to distinguish between
treatable active disease and irreversible untreatable disease-
related damage. In most patients, the disease resolves spontane-
ously without treatment (42.6% of patients in our series) or with
treatment (10.4% of our patients). Some authors have suggested
classifying sarcoidosis as chronic when the disease remains active
for more than 2 years.[21] However, chronicity is currently
accepted when the disease remains active for more than 5 years,
since a significant number of patients become inactive between 2
and 5 years spontaneously or under treatment.[53] In our series,
28.1% of patients showed active disease for more than 5 years
and were classified as chronic sarcoidosis. However, patients
with chronic sarcoidosis may show a mild degree of activity
without clinically significant organ dysfunction, in what has been
called smoldering sarcoidosis (19.6% in our series), or with
moderate to severe organ damage (8.5% of our patients). Signs
and symptoms caused by organ damage may be a consequence of
still active disease, which is theoretically susceptible to some
response to therapy, or irreversible fibrosis, both often coexisting
in the same organ. Signs and symptoms caused by active
granulomatous inflammation and irreversible damage may be
initially similar and a major challenge is to distinguish between
these states in order to indicate appropriate therapy.
Treatment indications in sarcoidosis have been controversial for
many years, as clinicians have to bear in mind a range of
possibilities in evolution of the disease: spontaneous remission,
mild persistent disease for years with almost no clinical
repercussion, chronic disabling active disease, irreversible damage,
and, equally important, a balance between the benefits and side
effects of treatment. In our view, irreversible side effects caused by
treatment should be included in the concept of damage in
sarcoidosis. The main indications for treatment are symptomatic
pulmonary progressive disease with functional derangement, and
major extrapulmonary organ involvement.[31,47,63–68] In our
series, 45.3% of patients received treatment, most of them with
corticosteroids. A small but significant number of patients received
other immunosuppressive agents, usually in combination with
low-doses of corticosteroids. Anti-TNF therapieswere used in very
few cases. However, only about 10% of patients did complete
remission take place during treatment. In addition, inmost patients
with chronic sarcoidosis, treatment just helped to keep the disease
under relative control. These findings may put in question the true
efficacyof current treatments in sarcoidosis.Themost frequent and
clinically significant forms of end-stage organ damage were
pulmonary fibrosis, neurosarcoidosis, and cutaneous disfiguring
lesions such as lupuspernio. Pulmonaryfibrosis from sarcoidosis is
usually slowly progressive, and may range from asymptomatic to
be life-threatening because of the development of respiratory
failure, bronchiectasis, or pulmonary hypertension.[69–71]4.6. Predictor factors at diagnosis of chronic sarcoidosis
This study corroborates that Löfgren syndrome and the presence
of mediastinal lymphadenopathy are clinical factors associated9
with good prognosis, whereas advanced age, pulmonary, and
splenic involvement are associated with poor outcomes. These
results are similar to those reported by our previous and other
prognostic studies.[21,25,26,72] However, variables representing
some of the extrathoracic manifestations that have been
previously associated with poor prognosis in the literature, such
as cardiac sarcoidosis and others, did not reach statistical
significance because of the few patients with these manifestations
in our series (Table 6). In several studies the use of corticosteroids
has been associated with chronic sarcoidosis. An intense immune
response, as noted by BAL studies, is usually indicative of a
favorable outcome, and it has been hypothesized that its
suppression with corticosteroids may be harmful.[73] However,
it seems more plausible that the indications of therapy, according
to current guidelines, simply reflexes the more severe cases at the
beginning of the disease.[74] The important differences between
Löfgren syndrome and other forms of sarcoidosis in clinical
presentation and outcome, and the existence of at least 2 clear
genetic markers of Löfgren syndrome, such as HLA class II
haplotype DRB1∗0301 and CCR2-haplotype 2, strongly suggest
that they may represent distinct entities.[40]4.7. Comparison between the first 2 and last 2 decades
Our study allows a number of interesting comparisons to be
made. Firstly, the age of diagnosis increased slightly in the last 2
decades. This may be due to the frequency of patients with
Löfgren syndrome being much higher during the first 2 decades.
We believe that the main reason for the decrease of patients with
Löfgren syndrome in the last 2 decades is a more accurate
selection of difficult cases for referral from other centers.
Secondly, the detection of other organ involvement may have
increased with the introduction of more advanced imaging
techniques, despite data not always being statistically significant.
Finally, a clear increase in the use of steroid-sparing agents can be
observed in the last 2 decades.
Our study has some limitations. The high frequency of Löfgren
syndrome in our country limits comparisons with other series of
sarcoidosis based on different ethnicities. Besides, as we only
analyzed patients assessed at a tertiary reference center, the
sample selection could be somehow slightly biased. The study is
also limited by the observational nature inherent to studies of
clinical series of sarcoidosis. The follow-up of the patients was
not uniform, the analysis of cases was made at different moments
of their disease course, and some data were missed. The absence
of validated criteria to define the presence of activity of
sarcoidosis and in particular to evaluate the degree of organ
damage is an additional important limitation of the study as well.
In summary, the present observational and prognostic
investigation reports a 40-year overview of the clinical spectrum
and long-term follow-up of the disease in a large series of 640
patients with sarcoidosis at a single reference center in Barcelona,
Spain. This extended and consistent experience in managing a
large number of patients with sarcoidosis firmly emphasizes the
value of a multidisciplinary approach by specialized teams in the
clinical assessment and long-term follow-up of the disease.Acknowledgments
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